cause

[키워드] acute respiratory syndrome coronavirus Analysis anti-inflammatory agent anti-inflammatory agents Anti-viral Antibody Response approach attenuate binding blunt cause CD24 CD24Fc CD4 CD56 CD8 cellular compartments chemokine chemokines Clinical characteristics Clinical efficacy coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 severity cytokine Cytokine score Cytokines damage damage-associated molecular pattern Damage-associated molecular patterns demonstrated downstream enrolled epithelial cells Extracellular flow cytometry heat shock proteins homeostasis homology Immune homeostasis immunopathology Immunophenotyping induce infected individuals Inflammatory response Lung epithelial cells Natural killer cells Pathogenesis pathway Patient patients with COVID-19 performed Peripheral blood peripheral blood samples phosphatase placebo group pro-inflammatory cytokine Protein Randomized Release respiratory Result return SARS-CoV-2 SARS-CoV-2-infected individuals severe acute respiratory syndrome coronavirus 2 severe COVID-19 severity shown Siglec10 significantly Soluble CD24 supplementary material systemic cytokine response systemic inflammation T cell T cells therapeutic therapeutic efficacy Treatment Trial with COVID-19
[DOI] 10.1186/s13045-021-01222-y PMC 바로가기 [Article Type] Clinical Trial